WEDBUSH Downgrades SOLID BIOSCIENCES Target Price

Summary

Wedbush reduced the target price for Solid Biosciences Inc from $18 to $17, reflecting a reassessment of the company’s valuation and potential.Reuters

Impact Analysis

This event is at the company level as it specifically pertains to Solid Biosciences Inc. The target price adjustment by Wedbush could influence investor sentiment regarding the company’s stock. Recent related events include Solid Biosciences’ registration for up to $400 million in mixed securities and an $85 million common stock offering, which could impact the company’s capital structure and liquidity.Reuters+ 2 Additionally, analyst expectations for the company’s quarterly earnings report, predicting a loss of $0.56 per share, weigh on investor expectations.Reuters+ 2 The reduction in target price might suggest caution in the company’s growth prospects or market position, potentially affecting stock prices and investment strategies related to Solid Biosciences.